BIOGEN INC (BIIB) Stock Analyst Ratings
NASDAQ:BIIB • US09062X1037
196.52 USD
+1.02 (+0.52%)
At close: Feb 13, 2026
196.5 USD
-0.02 (-0.01%)
After Hours: 2/13/2026, 8:00:01 PM
ChartMill assigns a Buy % Consensus number of 73% to BIIB. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 195.32. This target is -0.61% below the current price.
- BIIB was analyzed by 42 analysts. The buy percentage consensus is at 73. So analysts seem to be have mildly positive about BIIB.
- In the previous month the buy percentage consensus was at a similar level.
- BIIB was analyzed by 42 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2026-02-10 | Wedbush | Maintains | Neutral -> Neutral |
| 2026-02-09 | TD Cowen | Maintains | Buy -> Buy |
| 2026-02-09 | Guggenheim | Maintains | Buy -> Buy |
| 2026-02-09 | BMO Capital | Maintains | Market Perform -> Market Perform |
| 2026-02-09 | RBC Capital | Maintains | Outperform -> Outperform |
| 2026-02-09 | Wedbush | Maintains | Neutral -> Neutral |
| 2026-02-09 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2026-02-09 | Truist Securities | Maintains | Hold -> Hold |
| 2026-02-09 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2026-02-09 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2026-02-09 | Citigroup | Maintains | Neutral -> Neutral |
| 2026-02-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-30 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2026-01-27 | Citigroup | Maintains | Neutral -> Neutral |
| 2026-01-08 | Truist Securities | Maintains | Hold -> Hold |
| 2026-01-07 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-12-12 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-12-10 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-12-10 | HSBC | Downgrade | Hold -> Reduce |
| 2025-11-21 | Piper Sandler | Reiterate | Neutral -> Neutral |
| 2025-11-06 | Stifel | Upgrade | Hold -> Buy |
| 2025-11-03 | Bernstein | Maintains | Market Perform -> Market Perform |
| 2025-10-31 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-10-10 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-09-25 | Jefferies | Initiate | Buy |
| 2025-09-24 | Needham | Reiterate | Hold -> Hold |
| 2025-09-04 | Needham | Reiterate | Hold -> Hold |
| 2025-08-14 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2025-08-01 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-08-01 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
BIOGEN INC / BIIB FAQ
What do analysts expect the price target to be for BIOGEN INC (BIIB)?
42 analysts have analysed BIIB and the average price target is 195.32 USD. This implies a price decrease of -0.61% is expected in the next year compared to the current price of 196.52.
What is the consensus rating for BIOGEN INC (BIIB) stock?
The consensus rating for BIOGEN INC (BIIB) is 73.3333 / 100 . This indicates that analysts generally have a positive outlook on the stock.